David Sheppard
Director/Board Member at Locki Therapeutics Ltd.
David Sheppard active positions
| Companies | Position | Start | End |
|---|---|---|---|
Locki Therapeutics Ltd.
 Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Director/Board Member | 2019-07-16 | - |
Revona Bio Ltd.
 Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | Director/Board Member | 2023-04-04 | - |
Career history of David Sheppard
Statistics
International
| United Kingdom | 3 |
Operational
| Director/Board Member | 2 |
Sectoral
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |
Revona Bio Ltd.
Revona Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Revona Bio Ltd. is a British biotechnology company that specializes in the development of RNA targeted drugs. The company was founded in 2022 by Anastasia Jane Callaghan and Charlotte Anne Henderson. | Commercial Services |
- Stock Market
- Insiders
- David Sheppard
- Experience
